Evidence map›Paper›PMID 42727249›Full record

ArticleEBioMedicine2026

Safety and efficacy of cisplatin and nab-paclitaxel pressurised intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal carcinomatosis: Nab-PIPAC phase 1b study.

Manuela Undurraga, Noemie Lang, Thibaud Koessler, Antonella Diciolla, Mariagrazia Di Marco, Nicolas Mach, Catherine Raimond, Vassilis Genoud, Valentine Du Bois, Jean-Christophe Tille and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Manuela UndurragaDivision of Gynecology, Department of Paediatrics, Gynecology and Obstetrics, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland. Electronic address: manuela.undurraga@hug.ch.
Noemie LangDepartment of Oncology, Geneva University Hospitals and Department of Medicine, Center of Translational Research in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Thibaud KoesslerDepartment of Oncology, Geneva University Hospitals and Department of Medicine, Center of Translational Research in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Antonella DiciollaDepartment of Oncology, Lausanne University Hospital CHUV, Lausanne, Switzerland.
Mariagrazia Di MarcoDepartment of Oncology, Geneva University Hospitals and Department of Medicine, Center of Translational Research in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Nicolas MachDepartment of Oncology, Geneva University Hospitals and Department of Medicine, Center of Translational Research in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Catherine RaimondDepartment of Oncology, Geneva University Hospitals and Department of Medicine, Center of Translational Research in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Vassilis GenoudDepartment of Oncology, Geneva University Hospitals and Department of Medicine, Center of Translational Research in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Valentine Du BoisDepartment of Oncology, Geneva University Hospitals and Department of Medicine, Center of Translational Research in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Jean-Christophe TilleDivision of Clinical Pathology, Department of Diagnostics, Geneva University Hospitals, Geneva, Switzerland.
Aurelie BornandDivision of Clinical Pathology, Department of Diagnostics, Geneva University Hospitals, Geneva, Switzerland.
Jonathan S MooreDepartment of Oncology, Geneva University Hospitals and Department of Medicine, Center of Translational Research in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Marc WeinerDepartment of Oncology, Geneva University Hospitals and Department of Medicine, Center of Translational Research in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Laure SmekensDepartment of Oncology, Geneva University Hospitals and Department of Medicine, Center of Translational Research in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
José L SandovalDepartment of Oncology, Geneva University Hospitals and Department of Medicine, Center of Translational Research in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Julie TerzicDepartment of Oncology, Geneva University Hospitals and Department of Medicine, Center of Translational Research in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Yann ChristinatDivision of Clinical Pathology, Department of Diagnostics, Geneva University Hospitals, Geneva, Switzerland.
Jennifer VeillardDivision of Clinical Pathology, Department of Diagnostics, Geneva University Hospitals, Geneva, Switzerland.
Petros TsantoulisDepartment of Oncology, Geneva University Hospitals and Department of Medicine, Center of Translational Research in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Paul ThoueilleService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland.
Thomas MercierService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland.
Stefan MonigDivision of Visceral Surgery, Geneva University Hospitals, Geneva, Switzerland.
Patrick PetignatDivision of Gynecology, Department of Paediatrics, Gynecology and Obstetrics, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Christian TosoDivision of Visceral Surgery, Geneva University Hospitals, Geneva, Switzerland.
Laurent DecosterdService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland.
Martin HübnerDepartment of Visceral Surgery, University Hospital CHUV and University of Lausanne (UNIL), Lausanne, Switzerland.
Intidhar Labidi-GalyDepartment of Oncology, Geneva University Hospitals and Department of Medicine, Center of Translational Research in Onco-Haematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland. Electronic address: Intidhar.labidi-galy@hug.ch.
Frederic RisDivision of Visceral Surgery, Geneva University Hospitals, Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlatinum and taxanes are backbone chemotherapy in multiple solid tumours. We aimed to investigate the safety, tolerability, and pharmacokinetics of nab-paclitaxel and cisplatin administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC).

methodsNab-PIPAC is a phase 1b trial investigating PIPAC administration of cisplatin at 10.5 mg/m

findingsWe enrolled 22 patients with peritoneal carcinomatosis, of whom 18 received at least one PIPAC: 6 ovarian, 9 gastric and 3 pancreatic cancers. Four patients (ovarian cancer) did not receive PIPAC due to bowel obstruction (n = 1) or no access to peritoneal cavity (n = 3). Median age was 67 years (43-81). In total, 45 PIPAC procedures were administered and 12 of 18 (67%) patients completed three PIPAC cycles. There was no dose limiting toxicity. The most common side effect was abdominal pain. One patient had grade 3 treatment related adverse event: bladder lesion requiring surgical reintervention. Median progression-free survival was 3.5 months and median overall survival was 9.4 months. Five patients with gastrointestinal cancer survived more than one year (3 gastric and 2 pancreatic). Pharmacokinetic analyses showed good linearity between nab-paclitaxel dose and the AUC

interpretationThe combination of nab-paclitaxel and cisplatin administered by PIPAC was safe and well tolerated in patients with peritoneal carcinomatosis. Further investigation of this combination is warranted.

fundingThe study was supported by la bourse jeune chercheur des Hopitaux Universitaires de Geneve (NL), Fondation Fond'action (ILG) and Fondation NOVA (ILG).

Indexed as

CisplatinGastricNab-paclitaxelOvarianPeritoneal carcinomatosisPIPAC

Identifiers

PMID42727249
PMCPMC13587052

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.